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Background: Tacrolimus (FK506) is an effective immunosuppressant for human heart 
transplantation, but information about its effects on cardiac allograft and nonallograft 
kidney and liver histopathologic study is limited. 
Methods: We therefore reviewed 1145 endomyocardial biopsy specimens and eight 
autopsy results from 80 heart transplant recipients who received tacrolimus as baseline 
immunosuppression. These were compared with 619 endomyocardial biopsy specimens 
and four autopsy results from 51 patients treated with cyclosporine-based 
immunosuppression with lympholytic induction (eLI) by use of rabbit anti-thymocyte 
globulin. Twenty-one histologic features including the International Society for Heart 
and Lung Transplantation histopathologic grade were retrospectively assessed without 
knowledge of the treatment regimen. The lymphocyte growth index on biopsy 
specimens obtained from these patients was also compared. 
Results: In general, there were no qualitative differences in the histopathologic 
appearance of various allograft syndromes between tacrolimus- and eLI-treated 
patients. Thus histopathologic criteria used to diagnose various graft syndromes are 
applicable under tacrolimus immunosuppression. However, early (between 10 and 30 
days) after transplantation, biopsy specimens from patients treated with tacrolimus 
showed a significantly higher percentage of inflamed fragments (p = 0.02), the 
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inflammation tended to be more severe (p = 0.09). and the rejection grade tended to 
be slightly higher (p = 0.08). In contrast, during the late transplantation period (275 to 
548 days), biopsy specimens from patients treated with CLI showed a significantly 
higher percentage of inflamed fragments (p = 0.03), more severe inflammation (p = 
0.03), higher rejection grades (p = 0.01), and a higher frequency of Quilty lesions (p = 
0.05). Although overall freedom from any grade 3A or higher rejection was greater in 
the CLI-treated arm, tacrolimus was successfully used to treat refractory rejection in 
three patients from the CLI-treated arm. Concern has been raised in the literature 
about the possibility of tacrolimus being a direct hepatotoxin and an accelerant of 
allograft obliterative arteriopathy. However, no evidence to support either of these 
contentions was detected in this patient population. In contrast, tacrolimus is clearly 
nephrotoxic, although similar to cyclosporine in this regard. 
Conclusions: Tacrolimus is an effective immunosuppressive drug for heart 
transplantation. The cardiac allograft histopathologic study of patients treated with 
tacrolimus immunosuppression does not significantly differ from those given 
conventional. cyclosporine-based triple therapy with Iympholytic induction. J Heart 
Lung Transplant 1997;16:723-34. 
T acrolimus is an effective immunosuppressant 
that controls allograft rejection in a variety of ex-
perimental animal models. I-7 Excellent results have 
also been reported in early and randomized clinical 
trials of liver transplantation.8-14 Tacrolimus has also 
been shown to have therapeutic advantages in clin-
ical kidney,15-18 heart,19 and lung20 transplantation. 
In general, tacrolimus-treated recipients experience 
a lower incidence of and less severe acute rejection, 
less requirement of corticosteroids, and less chronic 
rejection; in addition, tacrolimus can effectively 
control rejection refractory to other forms of treat-
ment. However, little information is available about 
the effect of tacrolimus on the histopathologic study 
of human cardiac allograft rejection and possible 
adverse affects on other vital organs such as the 
kidney or liver of these recipients. 21 
We therefore reviewed the histopathologic fea-
tures and the associated clinical events of 80 adult 
cardiac allograft recipients who received tacroli-
. mus/steroids as the baseline immunosuppressive 
-a-gents. This group of patients was compared with 
a group of 51 patients who were treated with 
cyclosporine-based immunosuppression with Iym-
pholytic induction (CLI), which consisted of cyclo-
sporine, azathioprine, and steroids including in-
duction with anti thymocyte globulin. This was not 
a randomized trial: the two regimens were not 
directly comparable (i.e .• double versus triple 
therapy with antilymphocyte induction), and it 
was not our intent to compare the overall efficacy 
of tacrolimus to cyclosporine as an immunosup-
pressant. Rather, the purpose of this study was to 
compare the cardiac histopathologic findings in 
these two groups of patients and to determine 
whether there were specific hepatic or renal toxic 
manifestations attributable to tacrolimus. 
MATERIAL AND METHODS 
Patient Enrollment and Evaluation 
All adult cardiac allograft recipients who underwent 
transplantation at the University of Pittsburgh Med-
ical Center between October 8, 1989, and October 
16, 1993, because of irreversible end-stage heart 
failure (New York Heart Association class IV) were 
included in this study. Between October 8,1989. a'nd 
June 22, 1992, 76/85 (89.4%) of these patients chose 
the option of tacrolimus immunosuppression. after 
appropriate informed consent was obtained. The 
patients are a subset of those whose clinical course 
under tacrolimus was previously reported_ 1q This 
treatment regimen initially consisted of tacrolimus 
and corticosteroids, and later in the course, azathio-
prine was added in selected patients to reduce 
nephrotoxicity or to control rejection. The remain-
ing nine patients who underwent heart replacement 
during this time were given CLI, because of lack of 
informed consent (n = 3), unavailability of tacroli-
mus at the time of transplantation (n = 2), elevated 
creatinine (n = 1), or lack of insurance coverage 
(n = 1). In two cases the reasons were not clear. The 
population profile, cause(s) of heart failure, and 
allograft number at the time of entry into the study 
are listed in Table I. 
Tacrolimus was no longer available to those who 
underwent heart transplantation between June 27, 
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1992, and June 16, 1993. Forty-two (91.3%) of the 
46 patients who underwent transplantation during 
this time were routinely given CLI, which consisted 
of induction with rabbit anti-thymocyte globulin, 
followed by cyclosporine, azathioprine, and cortico-
steroids. The remaining four patients received ta-
crolimus because they underwent heart retransplan-
tation (n := 1), received a heart in combination with 
an extracardiac organ allograft (n := 2), or were 
treated under the pediatric protocol (n := 1). 
The operative procedure, details of the baseline 
immunosuppression regimens, patient management, 
and follow-up have been described elsewhere.19.22-24 
Pretransplantation cross-match and panel reactive 
antibodies (PRA) status before transplantation were 
determined with standard methods. All allografts 
were ABO blood group identical. 
All patients underwent endomyocardial biopsy 
once a week for the first 4 weeks after transplanta-
tion, one biopsy per month for the next 3 months, 
one biopsy every other month for the following 6 
months, and then, unless there was a clinical indi-
cation to biopsy, routinely every 6 months thereaf-
ter. Moderate or severe acute rejection (grade 3A or 
higher) were treated with pulse steroids (methyl-
prednisolone 1 gr/day intravenously for 3 consecu-
tive days) in both groups. Depending on the clinical 
circumstances, rejection episodes histopathologi-
cally graded as 1 B or 2, according to the Interna-
tional Society for Heart and Lung Transplantation 
criteria25 were treated slightly different in the two 
arms. In the tacrolimus group, when treated, these 
patients usually received augmentation of the ta-
crolimus alone, whereas patients treated with eLi 
were generally treated with corticosteroids. If a 
repeat endomyocardial biopsy performed within 2 
weeks after treatment for grade 3A or higher re-
vealed persistent rejection, the patient was treated 
with a course of OKT3 (5 mg/day intravenously for 
14 days or 10 mg/day for 5 days). If the rejection 
persisted or worsened, the patient was given OKT3 
(as above) or rabbit antithymocyte globulin (1.5 
mglkg/day administered intramuscularly for 5 days). 
The graft and patient status and posttransplanta-
tion clinical course were obtained from a retrospec-
tive review of the patient's records and discussion 
with the clinical transplant physicians. The closure 
of the study was on August 31, 1994, and complete 
follow-up was available until that date. 
Histopathologic Studies 
A total of 1145 allograft endomyocardial biopsy 
specimens and eight autopsy results were available 
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TABLE I Pre transplantation characteristics of the 
patient populations 
-------------------
Age 
Mean ± standard deviation 
Range 
Sex (male:female) 
Original disease, no. 
Ischemic cardiomyopathy 
Idiopathic dilated cardio-
myopathy 
Viral myocarditis 
Hypersensitivity myocarditis 
Valvular disease 
Congenital heart disease 
Amyloidosis (familial type) 
Rheumatic heart disease 
Other 
Allograft in place at initiation 
of study 
First 
Second 
Causes of primary allo-
graft failure 
Chronic rejection 
Acute rejection 
Atherosclerotic coro-
nary artery disease* 
Tacrolimus 
(N= 30) 
48.8 :!:: 10 
20-64 
64:16 
.+5 
19 
7 
:2 
:2 
:2 
75 
5 
4 
1 
0 
eLI 
(S = ;1) 
.+9.4 2: 9.6 
20-65 
45:06 
35 -----...--...-
9 
0 
0 
(I 
') 
-
II 
1 
-+ 
50 
1 
0 
0 
1 
*The histologic appearance of the lesions was more typical of 
atherosclerosis than of chronic obliterative arteriopathy associ-
ated with heart rejection. 
for review from patients in the tacrolimus arm. In 
the control group there were 619 allograft endomyo-
cardial biopsy specimens and four autopsy results. 
All tissue sections were reviewed by one of the 
authors (AT.) without knowledge of the immuno-
suppressive regimen, time after transplantation. or 
any additional treatment. A subset of at least 10% 
randomly chosen biopsy specimens and all of the 
autopsy results were also reviewed by two of the 
other authors (O.P. and AJ.D.). Slides for which 
there was any disagreement were reviewed together, 
and a consensus diagnosis was reached. Specific 
histopathologic features examined included the 
number of fragments; adequacy of the specimen; the 
number of inflamed fragments; the location 
(perivascular, interstitial, endocardial), distribution 
(focal. multifocal, diffuse), density (mild. moderate. 
severe), and cell type of inflammation (\ympho-
blasts, small lymphocytes, plasma cells. eosinophils, 
neutrophils. macrophages). if present; myocyte ne-
" . ~Dh , •. 
-
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crosis and dropout: interstitial edema, hemorrhage, 
and neutrophilia; arterial or venular inflammation; 
endocardial and interstitial fibrosis; endocardial in-
filtrates (Quilty effect); the presence or absence of 
granulation tissue and previous biopsy sites; and 
infectious organisms or posttransplantation Iympho-
proliferative disorders. Endocardial infiltrates, or 
Quilty lesions, were subclassified as endocardial 
(type A) or infiltrative (type B), according to ac-
cepted criteria.25 .2h If a patient had development of 
at least one biopsy specimen with an infiltrative 
Quilty effect, they were listed under the Quilty type 
B category. Finally, all of the biopsy specimens were 
retrospectively graded according to the Interna-
tional Society for Heart and Lung Transplantation 
classification scheme for acute rejection EAoFK~R In 
addition, the grade of acute rejection diagnosed at 
the time of surgical pathology sign-out was recorded 
and will be referred to as the "sign -ou t grade." 
For comparison and statistical analysis, the time 
after transplantation was arbitrarily separated into 
two intervals: early (corresponding to biopsy speci-
mens taken between 10 and 30 days after transplan-
tation) and late (corresponding to biopsy specimens 
obtained between 9 and 18 months after transplan-
tation). The early period was chosen because it 
encompasses the peak period of alloreactivity and 
rejection. The later period represents a more "qui-
escent" time. For the comparison of histologic study 
results early versus late, only patients who had 
biopsy specimens obtained during both time periods 
were included. 
Lymphocyte Growth Assays 
For lymphocyte functional analysis, three separate 
sterile fragments of endomyocardium were col-
lected, divided into smaller portions, and cultured in 
the presence of medium containing recombinant 
human interleukin-2 (Sandoz Pharmaceuticals, 
Basel, Switzerland) as previously described.27 The 
cultures were observed daily on an inverted phase 
-microscope, and a lymphocyte growth index was 
calculated on the basis of the number of fragments 
showing out-growth of lymphocytes in culture. For 
statistical analysis. the results for this assay were 
separated into three groups: those showing no 
growth; those in which growth was observed in 50% 
or less of fragments. and those in which more than 
50% of the fragments showed growth. 
Statistical Analysis 
Of the 1764 biopsy samples from 131 patients avail-
able for these analyses, 94 (5.3%) were excluded 
The Journal of Heart and Lung Transplantation 
July 1997 
because they were inadequate, and 12 (0.7'(:) from 3 
patients were excluded because they were obtained 
after the crossover of a patient from CLI to tacroli-
mus. The remaining 1658 (93.9%) biopsy specimens 
were included in this study. 
For the three patients whose treatment crossed 
over from CLI to tacrolimus, no data obtained after 
the crossover were included in the statistical analy-
sis. Because this was not a randomized clinical trial 
and the baseline comparability of the two groups is 
unknown, we chose not to analyze these data on the 
basis of "intention to treat." Regarding time to 
event analyses, none of these three experienced any 
of the outcomes of interest (death, grade 3A or 
greater rejection, or Quilty lesion) after the cross-
over. Thus no adverse outcomes have been omitted 
as a result of censoring. Similarly, for the compari-
sons of the histopathologic findings, all biopsy spec-
imens obtained after crossover were excluded to 
preclude the confounding of the comparisons of the 
two treatment regimens. 
Patients who received tacrolimus, in general, un-
derwent transplantation before those who received 
CLI and have longer total observed follow-up. To 
ensure appropriate comparisons between the two 
groups for al\ time-to-event analyses, we censored 
follow-up at 2 years after transplantation. The time-
to-event curves were generated by use of the 
Kaplan-Meier survival analysis method, and the 
Wilcoxon test was used to compare the curves. In 
addition, incidence rates for rejection were esti-
mated as the number of biopsy specimens showWlg 
grade 3A or greater rejection per 100 patient-days, 
and these rates were compared by use of a two-
sample test for incidence density measures. 2X 
Contingency table analyses were used to compare 
the histopathologic findings between the two treat-
ment groups and between early and late biopsies. 
Statistiqll comparisons were performed by use of a 
chi-square test for trend when the data were ordinal. 
Exact methods were used when required because of 
expected values less than 5 in individual cells of any 
contingency tables generated during these analyses. 
The Wilcoxon rank-sum test was used to compare the 
distribution of creatinine at both 1 and 2 years after 
transplantation between the two treatment groups. 
RESULTS 
Cardiac Histopathology 
Findings attributable to ischemic/preservation inju-
ry,29 such as focal areas of myocyte dropout, focal 
neutrophilia, edema, and hemorrhage without any 
associated mononuclear inflammation, were more 
The Journal of Heart and Lung Transplantation 
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TABLE II A Histopathologic data that showed a difference between the two treatment groups at 10 to 30 
days and at 1 year after transplantation: percent of inflamed fragments 
---------- ---~---------
CU Tacrolimus 
---""" 
--------
Time :\ 0·. 1%-50% 51%-100% N 0·' 10 1%-50% 51%-100% p Value 
10-30 days 49 28.6 26.5 44.9 75 10.7 28.0 61.3 0.02 
I year 40 30.0 40.0 30.0 70 50.0 34.3 15.7 0.03 
~"-----------
The value, listed are the percentage of patients showing the finding at that time. The p values refer to a comparison of tacrolimus to 
CLl-treated cases at the same time point. 
----.. ... ---
TABLE II B Histopathologic data that showed a difference between the two treatment groups at 10 to 30 
days and at 1 year after transplantation: inflammation intensity 
CLI Tacrolimus 
Time :\ None Minimal Mild > Mild N None Minimal Mild > Mild p Value 
10-30 days 49 2K6 10.2 44.9 16.3 75 10.7 24 38.7 26.7 0.09 
1 year 40 30.0 20.0 42.5 7.5 70 50.0 18.6 28.6 2.9 0.03 
The values listed are the percentage of patients showing the finding at that time. The p values refer to a comparison of tacrolimus to 
CLl-treat\!d cases at the same time point. 
TABLE II C Histopathologic data that showed a difference between the two treatment groups at 10 to 30 
days and at 1 year after transplantation: inflammation distribution 
Ttme 
10-30 days 
1 year 
N 
49 
40 
None 
28.6 
30.0 
eLI 
Diffuse 
12.2 
7.5 
Focal 
38.8 
60.0 
Mixed 
20.4 
2.5 
N 
75 
70 
None 
10.7 
50.0 
Tacrolimus 
Diffuse 
6.7 
4.3 
Focal 
60.0 
45.7 
Mixed 
22.7 
o 
p Value 
0.02 
0.06 
The values listed are the percentage of patients showing the finding at that time. The p values refer to a comparison of tacrolimus to 
CLI-treated cases at the same time point. 
commonly present or severe in biopsy specimens 
obtained between 10 and 30 days after transplanta-
tion than at 1 year (p < 0.001). However, no 
differences were observed between the treatment 
groups for any of those features at either time point. 
Previous biopsy sites, characterized early by partially 
organized endocardial fibrin masses and later by 
granulation tissue containing neutrophils, lympho-
cytes, and hemosiderin-laden macrophages and 
eventually fibrosis and myofiber disarray, were also 
more commonly detected early versus late (30.6% vs 
3.0%: p < 0.0001) after transplantation. Again, they 
were seen with similar frequency in both treatment 
groups. Table II shows data for the histopathologic 
findings that were different between the two treat-
ment groups. In the early biopsy specimens. the only 
statistically significant histopathologic differences 
between the two treatment groups were in the 
percentage of inflamed fragments, which was higher 
in the patients treated with tacrolimus (p = 0.02). 
and the distribution of the inflammation (p = 0.02). 
There also was a trend toward slightly more severe 
inflammation (p = 0.09) among the patients treated 
with tacrolimus. Late after transplantation, nearly 
the opposite trend was observed (Table II): the 
percentage of inflamed fragments was lower (p = 
0.03); and overall, there was less severe inflamma-
tion (p = 0.03) in the tacrolimus group. Perivascular 
and interstitial fibrosis were both significantly (p :s 
0.01) more severe among patients treated with ta-
crolimus. although in general, the difference ob-
served was between none and mild fibrosis. 
A separate analysis of the time to any Quilty 
lesion was performed (Figure 1). By 4 months after 
transplantation. the cumulative probability of the 
development of a Quilty lesion was 44.9% among 
the patients treated with eLI compared with only 
17.1 % among the patients treated with tacrolimus. 
By 2 years after transplantation, the corresponding 
probabilities are 65.6% and 49.S'C, respectively. 
-" -, I 
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Time to Any Quilty Lesion 
Cum. % remaining lesion free 
1MMn-------------------------------------~ 
80 
p=O.01 
60 
---------,--
o 91 182 273 364 455 546 637 728 
Days Post-Transplantation 
- ell (N=51) ---lac (N=80) 
FIGURE 1 Analysis of time until onset of any Quilty lesions. 
TABLE II D Histopathologic data that showed a difference between the two treatment groups with 
interstitial fibrosis and perivascular fibrosis at 1 year 
-----------------------
eLi Tacrolirnus 
-----"_."- ----.--
. 
N None Mild Moderate N None Mild Moderate p Value 
Interstitial fibrosis 
Perivascular fibrosis 
40 
40 
72.5 
100 
27.5 0 70 
0 0 70 
48.6 47.1 n 0.01 
84.3 15"7 U 0.007 
------"-------
The values listed are the percentage of patients showing the finding at that time" The p values refer to a compjrison of tacrolimus to 
eLI -treated cases at the same time poinL 
This difference in the incidence of a first Quilty 
" "" -~n during the first 2 years after transplantation is 
statistically significant (p = 0.01). 
Interestingly. in spite of the limited number of 
differences between drug regimens. there were sig-
nificant differences for almost all of the histopatho-
logic features examined when early biopsy speci-
mens were compared with those obtained later. 
regardless of the immunosuppressive treatment. 
The only parameters that did not show a significant 
difference in this comparison were the percentage of 
biopsy specimens containing plasma cells (p = 0.5), 
and the percentage of biopsy specimens showing 
mild perivascular fibrosis (p = OA). The presence or 
severity of endocardial fibrosis. interstitial fibrosis, 
and Quilty lesions were significantly (p < 0.001) 
greater on late biopsy specimens \erSUS early biopsy 
specimens. All other histologic features were signif-
icantly (p = 0.01 for endocardial inflammation, p < 
0.001 for all others) more common or severe early 
versus late. 
Grading of Rejection 
Freedom from histopathologic grade 3A or higher 
rejection, on the basis of the retrospective grading 
of rejection was higher in the eLi group during 
The Journal of Heart and Lung Transplantation 
Volume 16, Number 7 
Tsamandas ct a!. 729 
Signout Rejection Grade (10-30 days) 
p = 0.08 
Tacrolimus 
3A 38 
Rejection Grade 
Signout Rejection Grade (1 year) 
J!J 
c 
Q) 
+i 
ns 
c. 
.... 
o 
... 
c: 
Q) 
~ 
Q) 
c. 
p = 0.01 
Tacrolimus 
eLi 
Rejection Grade 3A 
FIGURE 2 Distribution of sign-out grade of acute rejection between patients treated with 
eLI and tacrolimus early (A) and late (B) after transplantation. 
the first 2 years after transplantation (p = 0.02). 
At 6 weeks after transplantation, 62.1 % of the 
patients treated with eLI and 49.1 ('( of the ta-
crolimus-treated recipients were free of grade 3A 
or higher rejection. The magnitude of this differ-
ence did not change at 2 years (41.1 ';' vs 28.5). 
The subtle differences in histopathologic findings 
noted above also translated into differences in the 
distribution of histopathologic sign-out grades of 
rejection. Early after transplantation, the sign-out 
grade of rejection (Figure 2A) tended to be 
slightly higher among patients treated with ta-
crolimus (p = 0.08). Late after transplantation the 
sign-out grade of rejection was significantly higher 
--
i j 
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.. atlent Survival 
Cum. % remalnint alive 
1 •• ~;=========~------------------~ 
- - - - - - - - - - - --:-K::--KK~-"Dt:"-=:_-::_:-:_:-c_=-=-_-::_-::_:-:_:-c------l 
I. i- .................. . 
1I='·5i 
i. 1- ................................................. . 
4. _ ....................................................... . 
2. _ ....................................................... . 
. ~--~----~--~--~----~--~----~--~ 
• 11 112 273 314 455 54i i37 721 
aays ".st-TransJlJantatl.n 
_ eLi (N=51) ._. Tae (N=80) 
FIGURE 3 Cumulative percentage of patients remaining alive after heart transplantation, 
according to treatment regimen. 
in the patients treated with CLI (p = 0.01), 
although it was still not enough to warrant addi-
tional immunosuppression in most patients (Fig-
ure 2,B). The estimate of a "linearized" rejection 
rate during the first 2 years after transplantation 
for each group revealed that there were 0.212 
episodes per 100 patient-days in the CLI group 
and 0.216 episodes per 100 patient days in the 
patients treated with tacrolimus (p = 0.98). 
It must be emphasized that this is not a study to 
compare the efficacy of tacrolimus versus CLl, be-
cause the two drugs were used differently. Tacrolimus 
. - WaHlsed in combination with prednisone alone. Aza-
thioprine was added if there was persistent rejection 
(grade 2 or higher on two consecutive biopsy speci-
mens) or if there was renal insufficiency (creatinine 
>2.5 mg/dl). Cyclosporine on the other hand, was used 
in combination with azathioprine, steroids and Iym-
pholytic induction therapy. Even though these differ-
ences existed, three patients treated with CLl were 
switched to tacrolimus 3. 4. and 12 months after 
transplantation for persistent and relapsing acute re-
jection. In all three, rejection was ultimately controlled 
when the next biopsy specimen was obtained 11, 18, 
and 20 days after conversion to tacrolimus, and they 
have had an uncomplicated course since conversion to 
tacrolimus. 
In total there were six episodes of clinically seri-
ous rejection that were pathologically graded as 
moderate or severe (grade 3A or 3B). Four of these 
episodes failed to respond to primary or secondary 
therapy, including the use of OKTJ (ll = 4), and all 
four patients died. In three of the patients who died 
(tacrolimus, 1I = 2; CLl, fl = 1). endomyocardial 
biopsy specimens obtained before death underesti-
mated the severe rejection first documented with 
certainty at autopsy. One other patient treated with 
CLl died during OKT3 therapy for severe rejection 
recognized before death. 
Lymphocyte Growth 
In spite of the histopathologic difference in the 
intensity of inflammation and the grading of rejec-
tion between the t\vo groups, there were no statisti-
cally significant differences in the rate of biopsy 
growth when comparing patients treated with the 
different drug regimens either early or late after 
transplantation. However, lymphocyte growth from 
r 
I 
I t ~ .. 
---
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biopsy fragments was significantly greater (p < 
0.0001) in those biopsy specimens obtained early. in 
comparison to late biopsy specimens after transplan-
tation. regardless of the treatment regimen. 
Patient and Allograft Sunhal 
No patients underwent heart retransplantation, and 
those experiencing allograft failure died. The cumu-
lative percent surviving .2 years after transplantation 
was 84.99C among patients treated with tacrolimus 
and 90.09C among patients treated with CLI (p = 
0.56; Figure 3). A complete listing of the causes for 
death in both groups is given in Table III. It should 
be stressed that follow-up for the tacrolimus group 
was longer than for the CLI group. For statistical 
analysis. a common follow-up time is important. 
However. we wanted to provide the maximum 
amount of information. so all follow-up information 
until closure of the study is included in Table III. 
"ascular, Renal, and Hepatic Structure 
and Function 
Arterial medial necrosis has been reported as a side 
effect of tacrolimus in early experimental animal 
studies:'o.31 However, subsequent studies found sim-
ilar lesions in untreated allograft recipients and in 
those treated with other immunosuppressive 
agents.7..12.34 In this study. necrotizing or inflamma-
tory arteritis was not detected with certainty in any 
biopsy specimen. At autopsy, arterial inflammation 
and necrosis were only seen in the cardiac allografts 
of patients with severe rejection. 
Overall. serious nephrotoxicity requiring either 
dialysis or kidney transplantation was seen in four 
patients treated with tacrolimus and two patients 
treated with eLI before closure of the study, al-
though the patients treated with tacrolimus had a 
longer follow-up. No patient from either group was 
treated with dialysis before transplantation. Only 
one patient treated with CLI who experienced kid-
ney failure underwent a needle biopsy of her native 
kidney 1.8 years after transplantation. The biopsy 
specimen showed mild interstitial fibrosis and mild 
arterial and hyaline arteriolonephrosclerosis,.consis-
tent with chronic cyclosporine nephrotoxicityY This 
patient died of chronic rejection 216 days after the 
kidney biopsy specimen was obtained. 
All other liver and kidney tissue samples from 
these patients were obtained at the time of autopsy. 
No pretransplantation kidney or liver biopsy speci-
mens were available for comparison, to determine 
whether any of the changes observed progressed 
during tacrolimus or CLI therapy. Table IV summa-
Tsamandas et al. 731 
TABLE III Causes of death after transplantation, 
listed according to the primary 
immunosuppressive regimen 
Cause of death 
Acute rejection 
Chronic rejection 
Sepsis 
Pancreatitis 
Right ventricular failure 
Recurrent and metastatic atrial 
sarcoma 
Liver failure (hepatitis type 8) 
Cardiac arrhythmia (hyperkale-
mia) 
Pulmonary and gastrointestinal 
hemorrhage 
Ischemic cardiac disease 
Died during repair of right groin 
Pseudoaneurysm 
Not determined with certainty 
Tacrolimus 
(.\'·80) 
,* 
3 
4 
2 
1 
0 
0 
Total Deaths (o/c of total) 17 (21)t 
CLI 
(S·51 ) 
2 
2 
0 
0 
0 ---- ........ -
0 
0 
0 
6 (12)t 
'In one patient, the rejection was superimposed on preservation 
injury. characterized by multiple areas of myocyte dropout. The 
patient also had a large pulmonary thromboembolus and acute 
cor pulmonale. 
tin five patients treated with tacrolimus and one patient treated with 
eLl death occurred more than 2 years after transplantation. which 
is after the cut-off follow-up time for statistical analysis (see text). 
rizes the kidney and liver histopathologic findings 
and the drug blood levels immediately before death. 
The most common renal changes observed at au-
topsy in both groups were patchy interstitial fibrosis 
with associated tubular atrophy: mild to moderate 
arterial and arteriolonephrosclerosis; focal periglo-
merular fibrosis and acute tubular necrosis presum-
ably associated with agonal events. One patient 
treated with tacrolimus with end-stage kidneys at 
autopsy had undergone dialysis for 1.5 years before 
death. He had normal renal function before heart 
transplantation 3.5 years earlier. 
There was no direct correlation between plasma 
tacrolimus levels and hepatic structure. However. 
heart failure and ischemic injury frequently compli-
cated hepatic histologic study at autopsy (Table IV). 
Although this may have obscured any histopatho-
logic findings attributable to tacrolimus hepatic tox-
icity, the changes were acute in nature and likely 
caused by agonal events. 
DISCUSSION 
Single-institution and randomized multicenter re-
ports on the use of tacrolimus in liverI~·tOK1~ kid-
; 
-
--
.. 
t' : 
... ~K 
I 
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TABLE IV Native kidney and liver disease at autopsy in heart allograft recipients treated with tacrolimus 
Days after Plasma tacrolimus 
transplantation Cause of death levels (nglml) Kidney histopathology Liver histopathology 
10 Gastrointestinal and intra- 0.7 Mild ANS, mild IF. ATN Perivenular fibrosis 
10 
29 
30 
267 
376 
62-1 
1230* 
pulmonary hemorrhage 
Acute rejection superim-
posed on preservation 
injury and pulmonary 
thromboembolis 
Acute vascular rejection 
Pancreatitis and cardio-
genic shock 
Septic pulmonary throm-
boembolis 
Chronic rejection 
Right ventricular failure 
from pulmonary artery 
stenosis 
Myocardial infarct from 
chronic rejection 
------------- -----
2.-1 
1.2 
30.0 
2.1 
NA 
2.8 
2.0 
Mild ANS, tubular vacu-
olization 
Mild IF, ANS 
Unremarkable 
Mild IF, ANS 
Mild IF, ANS 
Minimal changes 
Endstage kidneys 
and passive conges-
tion 
Unremarkable 
Mild passive conges-
tion. cholestasis 
Widespread acute cen-
trilobular coagulative 
necrosis 
Passive congestion 
Mild portal fibrosis. 
chronic portal in-
flammation and mild 
congestion 
Perivenular hemor-
rhage 
Acute midzonal hepa-
tocyte dropout 
ANS. Arterial and arteriolonephrosclerosis: IF. interstitial fibrosis: A TN. acute tubular necrosis. 
'This patient died after the cut-off for follow·up time used in statistical analysis. 
ney,15.IR.36 lung,2U and heart transplantation 19 have 
already shown a therapeutic advantage for this 
agent, compared with cyclosporine-based immuno-
suppression. The major benefits of tacrolimus in the 
above clinicopathologic studies are greater overall 
freedom from acute rejection; less refractory acute 
rejection. less chronic rejection; a lesser require-
ment for steroids; dose maneuverability of the base-
line immunosuppressant agent as treatment for re-
jection; and the ability to rescue patients treated 
with CLI with refractory rejection, who had failed to 
--respond to steroid and lympholytic therapy. 
The primary purpose of this study was to compare 
the histopathologic findings in heart transplant re-
cipients treated with tacrolimus to the findings ob-
served in patients who received a cyclosporine-
based regimen. Overall, we could not detect any 
significant qualitative differences in the histopatho~ 
logic appearance of the various graft syndromes in 
patients treated with CLI versus tacrolimus. Thus 
one need not alter criteria used to diagnose rejec-
tion or other abnormalities seen in endomyocardial 
biopsies when tacrolimus is used. However, there 
were quantitative differences in the overall severity 
of inflammation and rejection between the two 
groups, which varied with time. 
Early after transplantation the overall severity of 
inflammation and incidence and grade of rejection was 
higher in the patients treated with tacrolimus. These 
results are similar to the findings in our clinical re-
port: l ,! a greater freedom from grade 3A or higher 
rejection was observed in the patients treated with CLI 
compared with the tacrolimus recipients. 1'1 In contrast. 
late after transplantation the trend was reversed: the 
overall severity of inflammation and incidence and 
grade of rejection was higher in the patients treated 
with CLI. These observations are likely attributable to 
the antithymocyte globulin induction I" for the follow-
ing reasons: the differences between the two groups 
appeared during the early posttransplantation period: 
and tacrolimus-treated patients experienced less rejec-
tion than cyclosporine-treated patients who did not 
receive lympholytic induction.J9 We must emphasize, 
however, that the primary purpose of this study was 
not to study the effectiveness of tacrolimus compared 
with cyclosporine in preventing acute rejection. We 
did not include cyclosporine-treated patients who did 
not receive lympholytic induction and pediatric recip-
ients, who do not undergo the same endomyocardial 
biopsy protocol as in the adults. Both of these groups, 
however, were included in our larger clinical analysis. 19 
Another more speculative explanation for these 
The Journal of Heart and Lung Transplantation 
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time differences is that the effect is not drug specific. 
It may reflect the consequences of overimmunosup-
pression in the early posttransplantation period. 
Hepatic allograft recipients who experienced early 
mild acute rejection but did not have development 
of significant dysfunction and were not treated with 
increased immunosuppression had development of 
less chronic rejection than those who did receive 
additional therapy for acute rejection.37 Thus early 
controlled alloreactivity may have long-term bene-
fitpKP~ Unfortunately. all of these explanations must 
remain speculative in nature. because none of them 
can be proven with certainty by use of the data from 
this study. 
Another interesting observation is the higher in-
cidence of Quilty lesions in the patients treated with 
eLI compared with those maintained with tacroli-
mus. The importance of this difference is unknown 
because the immunobiologic significance of Quilty 
lesions has yet to be determined with certainty.w In 
our recently developed experimental animal model 
of chronic rejectionK~o Quilty lesions were associated 
with low-grade immunologic damage to the allo-
graft. They were present in cardiac allografts under-
going chronic rejection but absent from allografts 
tolerated by the host:~o 
Previous experimental animal studies have raised 
concerns about the possibility of tacrolimus enhanc-
ing or promoting the development of graft vascu-
lopathy in cardiac allografts:H Although the number 
of patients in whom the heart was examined at 
autopsy was small. there was no significant increase 
in patients treated with tacrolimus for either the 
incidence of chronic rejection or intimal thickening 
of arteries in patients who died of other causes. 
Coronary angiography showing a statistically nonsig-
nificant lower incidence of graft vasculopathy in the 
tacrolimus grouplY has also assuaged some of these 
concerns. In addition, tacrolimus has been the only 
new immunosuppressant to significantly prolong the 
half-life of human renal allografts, 1~ where chronic 
rejection is responsible for most late graft failures. 
In two separate recent publications from the same 
institution. Fisher et a\.42 and Hytiroglou et ayK4~ have 
suggested that tacrolimus is a direct hepatotoxin, 
which causes perivenular hepatocellular necrosis. Clin-
ically significant hepatotoxicity was not a problem in 
this patient population. In fact, none of the patients in 
this study required modulation of tacrolimus doses 
because of hepatotoxicity. Unfortunately, all of the 
liver specimens were obtained at autopsy and had 
complicating histopathologic changes. which were at-
tributed to multiorgan failure. A clear correlation 
between drug levels~ and structure was not possible. 
Therefore the question of tacrolimus-associated hep-
Tsamandas et al. 733 
atotoxicity is probably best addressed in liver needle 
biopsy specimens from nonhepatic allograft patients 
maintained on tacrolimus. 
In contrast, tacrolimus is clearly nephrotoxic.44A5 
The range of histopathologic renal lesions associated 
with tacrolimus are quite similar to cyclosporine neph-
rotoxicity~RK4S and have been reported in detail..g-46 We 
were struck, however, by the heterogeneity of kidney 
disease in this heart transplant population: one patient 
who had received tacrolimus for only 10 days before 
death showed interstitial fibrosis and glomerulosclero-::---------
sis; whereas another patient who had been treated for 
624 days showed only minimal renal histopathologic 
alterations. Therefore one should be aware that signif-
icant underlying kidney disease may be present before 
heart transplantation and that the comorbid condition 
might accelerate or contrihute to the nephrotoxicity 
associated with the immunosuppressive agents. 
In summary, tacrolimus is an effective immuno-
suppressive drug for heart transplantation, The car-
diac allograft histopathologic study of patients 
treated with tacrolimus immunosuppression does 
not significantly differ from those given conven-
tional, cyclosporine-based triple therapy, 
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